Skip to content
10-Q

Quarterly Report

Taysha Gene Therapies, Inc. TSHA

0000950170-25-072036

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 15, 2025 214.66M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $42.45M
Long Term Debt Q1 2025 · Dec 31, 2024 $43.94M
Current Liabilities Q1 2025 · Mar 31, 2025 $22.56M
Current Liabilities Q1 2025 · Dec 31, 2024 $26.23M
Total Liabilities Q1 2025 · Mar 31, 2025 $83.3M
Total Liabilities Q1 2025 · Dec 31, 2024 $88.84M
Current Assets Q1 2025 · Mar 31, 2025 $120.71M
Current Assets Q1 2025 · Dec 31, 2024 $142.13M
Total Assets Q1 2025 · Mar 31, 2025 $138.36M
Total Assets Q1 2025 · Dec 31, 2024 $160.36M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $139.04M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $123.98M
Shares Diluted Q1 2025 · Mar 31, 2024 231.25M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$19.8M
Stockholders Equity Q1 2025 · Mar 31, 2024 $53.85M
Stockholders Equity Q1 2025 · Dec 31, 2023 $74.94M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.10
Eps Basic Q1 2025 · Mar 31, 2024 −$0.10
Sga Expense Q1 2025 · Mar 31, 2024 $7.08M
Rd Expense Q1 2025 · Mar 31, 2024 $20.66M
Net Income Q1 2025 · Mar 31, 2024 −$24.06M
Operating Income Q1 2025 · Mar 31, 2024 −$24.33M
Revenue Q1 2025 · Mar 31, 2024 $3.41M